TRADING UPDATES: Beeks in "strong" year; Iofina output up
15th Jul 2026 11:30
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
| Price | 1.275p on 31-07-2026 at 18:35:08 |
|---|---|
| Change | 0.00p 0% |
| Buy | 1.35p |
| Sell | 1.20p |
| Last Trade: | Buy 250,631.00 at 1.2911p |
| Day's Volume: | 288,395 |
| Last Close: | 1.275p |
| Open: | 1.275p |
| ISIN: | GB0034330679 |
| Day's Range | 1.275p - 1.275p |
| 52wk Range: | 0.85p - 7.50p |
| Market Capitalisation: | £14.49m |
| VWAP: | 1.295408p |
| Shares in Issue: | 1.14b |
Cellbxhealth (CLBX) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Buy* | 250,631 | 1.2911p | Ordinary |
14:43:00 - 31-Jul-26 |
| Buy* | 37,764 | 1.324p | Ordinary |
10:44:20 - 31-Jul-26 |
| Buy* | 5,143 | 1.324p | Ordinary |
15:37:24 - 30-Jul-26 |
| Buy* | 625 | 1.35p | Ordinary |
13:24:53 - 30-Jul-26 |
| Buy* | 25,711 | 1.291p | Ordinary |
11:46:05 - 30-Jul-26 |
| Buy* | 994 | 1.29p | Ordinary |
11:43:38 - 30-Jul-26 |
| Buy* | 15,000 | 1.29p | Ordinary |
09:51:50 - 30-Jul-26 |
| Buy* | 40,000 | 1.29p | Ordinary |
09:51:40 - 30-Jul-26 |
| Buy* | 17,000 | 1.324p | Ordinary |
09:30:51 - 30-Jul-26 |
| Buy* | 25,000 | 1.29p | Ordinary |
08:48:17 - 30-Jul-26 |
Cellbxhealth (CLBX) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 16th Jul 2026 7:00 am | RNS | Issue of Share Options |
| 15th Jul 2026 7:00 am | RNS | Q2 and First Half Year Results ended 30 June 2026 |
| 14th Jul 2026 9:46 am | RNS | Result of AGM |
| 14th Jul 2026 7:00 am | RNS | AGM Statement |
| 6th Jul 2026 4:45 pm | RNS | Directorate change |
| 22nd Jun 2026 7:00 am | RNS | Preliminary Results |
| 16th Jun 2026 7:00 am | RNS | Notice of Results |
| 29th May 2026 7:00 am | RNS | MSA with Global Pharmaceutical Company |
| 18th May 2026 7:00 am | RNS | Collaboration with AdventHealth for two studies |
| 11th May 2026 7:00 am | RNS | Q1 trading update and outlook for 2026 |